Search Orphan Drug Designations and Approvals
-
Generic Name: | autologous genetically engineered T cells that express a single-domain antibody that recognizes human mesothelin fused to the cluster of differentiation 3e subunit of the T cell receptor |
---|---|
Date Designated: | 02/01/2019 |
Orphan Designation: | Treatment of mesothelioma |
Orphan Designation Status: | Designated/Designation Withdrawn or Revoked |
Date Designation Withdrawn or Revoked: | 01/16/2024 |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
TCR2 Therapeutics, Inc., a wholly owned subsidiary of Adaptimmune Therapeutics plc 100 Binney Street Suite 710 Cambridge, Massachusetts 02142 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-